OmniAb (OABI) Interest & Investment Income (2022 - 2026)
OmniAb (OABI) posted quarterly Interest & Investment Income of $487000.0 for Q1 2026, down 9.31% year-over-year from $537000.0 in Q1 2025, and down 60.24% quarter-over-quarter from $1.2 million in Q4 2025.
Powered by 
Analysis
OmniAb (OABI) Interest & Investment Income (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported Interest & Investment Income for 5 consecutive years, with $487000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 9.31% year-over-year to $487000.0; the TTM figure through Mar 2026 stood at $2.6 million (down 2.17% YoY), while the FY2025 annual figure was $2.7 million, down 14.36% from the prior year.
- Interest & Investment Income fell to $487000.0 in Q1 2026 per OABI's latest filing, from $1.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.3 million in Q1 2023 and bottomed at $436000.0 in Q2 2025.
- Historically, Interest & Investment Income has averaged $849642.9 across 5 years, with a median of $738000.0 in 2024.
- Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 101.19% — and 2024, when it slumped 45.38%.
- OmniAb's Interest & Investment Income stood at $587000.0 in 2022, then surged by 101.19% to $1.2 million in 2023, then tumbled by 44.54% to $655000.0 in 2024, then soared by 87.02% to $1.2 million in 2025, then plunged by 60.24% to $487000.0 in 2026.
- Business Quant data shows OABI's Interest & Investment Income at $487000.0 in Q1 2026, $1.2 million in Q4 2025, and $462000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | OmniAb | 571.75 Mn | 519.75 Mn | 12.81 Mn | 434,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 434,000.00 |
| Mar 31, 2026 | 487,000.00 |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 462,000.00 |
| Jun 30, 2025 | 436,000.00 |
| Mar 31, 2025 | 537,000.00 |
| Dec 31, 2024 | 655,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 785,000.00 |
| Mar 31, 2024 | 975,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 587,000.00 |